Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.
Chronic azithromycin is commonly used in cystic fibrosis (CF) based on short, controlled, clinical trials showing reductions in pulmonary exacerbations (PEx) and improved FEV1. Long term effects are unknown. Examine pulmonary outcomes among chronic azithromycin users compared to matched controls over years of use, and consider combined azithromycin use in cohorts using chronic inhaled tobramycin or aztreonam. Retrospective cohort study using the U.S. CF Foundation Patient Registry. Incident chronic azithromycin users were compared to matched controls by FEV1 percent predicted rate of decline and rates of intravenous antibiotic use to treat PEx. Propensity score methods were utilized to address confounding by indication. Pre-defined sensitivity analyses based on lung function, Pseudomonas aeruginosa (PA) status, and follow-up time intervals were conducted. Across 3 years, FEV1 percent predicted per year decline was nearly 40% less in those with PA using azithromycin compared to matched controls (slopes -1.53 vs -2.41 pp/yr, difference: 0.88; 95% CI: [0.30, 1.47]). This rate of decline did not differ based on azithromycin use in those without PA. Among all cohorts, use of IV antibiotics was no different between azithromycin users and controls. Users of inhaled tobramycin and azithromycin had FEV1 percent predicted/year decline of -0.16 versus non-users (95% CI: [-0.44, 0.13]), while users of inhaled aztreonam lysine and azithromycin experienced a mean 0.49 pp/year slower decline than matched controls (95% CI:[-0.11, 1.10]). Results from this study provide additional rationale for chronic azithromycin use in PA positive individuals to reduce lung function decline. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).